NewAmsterdam Pharma's CFO will discuss their developments in LDL-lowering therapies at the Guggenheim Conference on February 5, 2025.
Quiver AI Summary
NewAmsterdam Pharma Company N.V., a biopharmaceutical firm focused on developing oral, non-statin treatments for patients at risk of cardiovascular disease due to high LDL cholesterol, announced that CFO Ian Somaiya will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 5, 2025. The event will be accessible via a live webcast on the company's investor relations website, with an archived replay available afterward. NewAmsterdam is conducting phase 3 trials for its lead candidate, obicetrapib, which aims to provide a safe and effective LDL-lowering option for patients intolerant to existing therapies.
Potential Positives
- Participation in a notable industry conference (Guggenheim SMID Cap Biotech Conference) enhances visibility and credibility in the biopharmaceutical market.
- Announcement underlines the company's focus on addressing unmet medical needs in cardiovascular disease, potentially attracting attention from investors and healthcare stakeholders.
- Live webcast of the fireside chat provides an opportunity for direct engagement with investors, fostering transparency and communication.
- Ongoing phase 3 trials for obicetrapib highlight the company's commitment to developing innovative therapies, which may appeal to potential partners and investors.
Potential Negatives
- Announcement highlights the reliance on a single investigational therapy, obicetrapib, raising concerns about the company's long-term viability if trials do not meet expectations.
- Company's focus on addressing an unmet need in a competitive market may indicate pressure to deliver results quickly, potentially leading to future operational challenges.
FAQ
What is NewAmsterdam Pharma's focus?
NewAmsterdam Pharma develops oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C levels.
When will Ian Somaiya participate in the Guggenheim Conference?
Ian Somaiya will participate in the fireside chat on February 5, 2025, at 10:00 a.m. ET.
How can I watch the fireside chat?
A live webcast of the fireside chat will be available on NewAmsterdam Pharma's investor relations website.
What is obicetrapib?
Obicetrapib is an oral, low-dose CETP inhibitor being investigated as an LDL-C lowering therapy.
Where can I find more information about NewAmsterdam Pharma?
More information can be found on the NewAmsterdam Pharma website under the investor relations section.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NAMS Insider Trading Activity
$NAMS insiders have traded $NAMS stock on the open market 28 times in the past 6 months. Of those trades, 2 have been purchases and 26 have been sales.
Here’s a breakdown of recent trading of $NAMS stock by insiders over the last 6 months:
- NAP B.V. FORGROWTH has made 0 purchases and 25 sales selling 1,175,289 shares for an estimated $30,021,362.
- LOUISE FREDERIKA KOOIJ (Chief Accounting Officer) sold 45,000 shares for an estimated $707,400
- MICHAEL H. DAVIDSON (Chief Executive Officer) purchased 5,000 shares for an estimated $81,350
- JULIETTE BERANGERE AUDET (Chief Business Officer) purchased 1,104 shares for an estimated $17,332
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NAMS Hedge Fund Activity
We have seen 67 institutional investors add shares of $NAMS stock to their portfolio, and 26 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC added 2,978,263 shares (+291.9%) to their portfolio in Q4 2024, for an estimated $76,541,359
- MILLENNIUM MANAGEMENT LLC removed 1,148,680 shares (-98.6%) from their portfolio in Q3 2024, for an estimated $19,068,088
- ARTAL GROUP S.A. removed 800,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $13,280,000
- WOODLINE PARTNERS LP added 681,289 shares (+140.9%) to their portfolio in Q3 2024, for an estimated $11,309,397
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 628,251 shares (+5.1%) to their portfolio in Q3 2024, for an estimated $10,428,966
- JANUS HENDERSON GROUP PLC added 520,772 shares (+51.1%) to their portfolio in Q3 2024, for an estimated $8,644,815
- POLAR CAPITAL HOLDINGS PLC added 502,414 shares (+50.1%) to their portfolio in Q3 2024, for an estimated $8,340,072
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 10:00 a.m. ET.
A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com . Following the live webcast, an archived replay will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
[email protected]
Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
[email protected]
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
[email protected]